Log In
BCIQ
Print this Print this
 

Biosimilar insulin glargine (Basalog)

  Manage Alerts
Collapse Summary General Information
Company Biocon Ltd.
DescriptionBiosimilar insulin glargine
Molecular Target
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes; Treat Type II diabetes
Regulatory Designation
PartnerFujifilm Holdings Corp.;
Mylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$200.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/18/2013

Undisclosed

Undisclosed

Undisclosed

10/25/2010

Undisclosed

$200.0M

Undisclosed

Get a free BioCentury trial today